
Gland Pharma Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Gland Pharma Receives Approval from USFDA for Latanoprostene Bunod Ophthalmic Solution".
Filed with NSE ·

Gland Pharma Limited has informed the Exchange regarding a press release dated April 30, 2025, titled "Gland Pharma Receives Approval from USFDA for Latanoprostene Bunod Ophthalmic Solution".
6ix hasn’t read this filing yet.
Follow Gland Pharma into a list and get an email when it puts out news.
Follow Gland Pharma